...Co. and RA Capital Management and existing investors Atlas Venture, SV Health Investors, Takeda Ventures, RiverVest Venture Partners...

...prior CEO, Niall O’Donnell, will remain on its board. He is a managing director at RiverVest Venture Partners...
...others. Returning investors include New Enterprise Associates, Pappas Capital and Lundbeckfonden Ventures, as well as RiverVest.TARGETSPPARδ...

...to move forward. The company’s investors include Arix, BioMed Ventures, New Enterprise Associates, Pappas Capital, RiverVest Venture Partners...

...participation from existing investors New Enterprise Associates, Arix Bioscience plc (LSE:ARIX), Lundbeckfonden Ventures, Pappas Capital, RiverVest Venture Partners...

...from new investor Pivotal bioVenture Partners and existing investors F-Prime Capital Partners, Novo Holdings A/S, RiverVest Venture Partners...

...led the financing with participation from fellow new investors SV Health Investors, MRL Ventures Fund, RiverVest Venture Partners...

...Spruce Biosciences Inc., announced late Wednesday. Joining them were existing investors Novo Holdings A/S and RiverVest Venture Partners...

...a 17.3% share. Other shareholders are Novo Holdings A/S with 10.4%, Shire with 10.3%, and RiverVest...

...to New Enterprise Associates, other investors in the round include Lundbeckfonden Ventures, Pappas Capital and RiverVest Venture Partners...
...employees: 9 Funds raised: $50 million Investors: New Enterprise Associates, Lundbeckfonden Ventures, Pappas Capital and RiverVest Venture Partners...

...protein α (SIRPA; CD172a; SHPS-1) mAb. Lightchain led the round with participation from existing investors RiverVest Venture Partners...